Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05834335 |
| Other study ID # |
01042023 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
March 1, 2020 |
| Est. completion date |
April 1, 2023 |
Study information
| Verified date |
November 2023 |
| Source |
National MS Center Melsbroek |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
The investigators will conduct retrospective observational cohort study at the Nationaal
Multiple Sclerose Centrum (NMSC) Melsbroek (Belgium), which is a large center specifically
focusing on neurological management, multidisciplinary care and/or rehabilitation in patients
with MS.
Primary endpoint For each DMT category, as defined above, the proportion of patients with a
worse COVID-19 outcome (i.e., hospitalization and/or death) will be compared between those
'protected' versus 'unprotected' by vaccination at the time of SARS-CoV-2 infection.
Corrections will be applied for any eventual imbalance in demographics, potentially relevant
to COVID-19 outcome, between subgroups that are compared to each other, if
indicated/feasible.
Description:
Study design The investigators will conduct retrospective observational cohort study at the
Nationaal Multiple Sclerose Centrum (NMSC) Melsbroek (Belgium), which is a large center
specifically focusing on neurological management, multidisciplinary care and/or
rehabilitation in patients with MS.
General aim To explore the protective effect of COVID-19 vaccination in patients with MS,
stratified according to their DMT regimen (specifically isolating those treated with B-cell
depleting and S1PR modulating agents), against severe forms of the infection.
Data collection Since March 2020 (i.e., the onset of the first wave of spiking COVID-19 cases
in Belgium), clinical information of patients followed at the NMSC Melsbroek has been
collected in a local database in case of COVID-19 diagnosis, as confirmed by positive antigen
or polymerase chain reaction testing for SARS-CoV-2. The following variables were recorded:
patient identification number, date of COVID-19 diagnosis, age, sex, race (White/Caucasian,
Black/African-American, Asian, other), known co-morbidities (cerebro- and/or cardiovascular
disease, arterial hypertension, smoking, dyslipidemia, diabetes mellitus, obesity), Expanded
Disability Status Scale (EDSS) score (based on the most recent medical report prior to the
infection), MS disease duration, clinical MS subtype, DMT regimen, COVID-19 severity
(ambulatory care versus hospitalization versus death), general vaccination status
(non-vaccinated versus fully vaccinated versus fully vaccinated + booster), date of last
vaccine administration prior to the infection. On December 1, 2022, our database was locked
for the present study and consisted of 450 COVID-19 cases (417 unique patients) with complete
data.
Patients will be stratified according to their DMT regimen at the time of COVID-19,
generating the following categories: (1) anti-CD20 B-cell depleting agents, (2) S1PR
modulating agents, (3) all other forms of DMT, (4) no DMT. In each DMT category, patients
will be labelled as either 'protected' or 'unprotected' by vaccination at the time of their
SARS-CoV-2 infection. Patients were considered to be 'protected' by vaccination if they were
(a) fully vaccinated and (b) tested positive for COVID-19 in the period ranging from 14 days
to 6 months after the last administered vaccine dose (which could also be a booster).
If the DMT category at the time of last vaccination differed from that at the time of
infection, patients will be excluded from the analyses; pulse corticosteroid treatment < 2
months prior to COVID-19 infection will account as an additional exclusion criterion.
Serum/plasma vitamine D levels, as measured the closest to the COVID-19 infection, if
available, will be extracted from the medical record for exploratory purposes.
Primary endpoint For each DMT category, as defined above, the proportion of patients with a
worse COVID-19 outcome (i.e., hospitalization and/or death) will be compared between those
'protected' versus 'unprotected' by vaccination at the time of SARS-CoV-2 infection.
Corrections will be applied for any eventual imbalance in demographics, potentially relevant
to COVID-19 outcome, between subgroups that are compared to each other, if
indicated/feasible.
